NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. Jeito will leverage its global network, expertise and strong value creation track record in immunology and...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies
Paris, France, November 29th 2023 - Jeito Capital (“Jeito”), a leading global investment company...
Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global,...
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new...
Jeito Capital renewed in “TIBI 2”
Paris, France, September 11th 2023 - Three years after being the 1st biopharma fund to be awarded...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.